STOCK TITAN

Organon (NYSE: OGN) CFO granted 404,840 RSUs and boosts share holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Organon & Co. Chief Financial Officer Matthew M. Walsh reported a series of equity compensation transactions in Organon common stock. On March 31, 2026, he was granted 321,368 restricted stock units (RSUs) and a separate grant of 83,472 RSUs, each RSU representing a contingent right to one share of common stock. These RSUs will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On the same date, portions of earlier RSU awards granted in 2023 and 2025 vested and were exercised into common stock, while 4,127 and 7,380 shares were withheld at $5.70 per share to cover tax obligations. Following these transactions, Walsh directly holds 212,746 shares of Organon common stock.

Positive

  • None.

Negative

  • None.
Insider WALSH MATTHEW M
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Restricted Stock Units 321,368 $0.00 --
Grant/Award Restricted Stock Units 83,472 $0.00 --
Exercise Restricted Stock Units 12,047 $0.00 --
Exercise Restricted Stock Units 21,546 $0.00 --
Exercise Common Stock 12,047 $0.00 --
Tax Withholding Common Stock 4,127 $5.70 $24K
Exercise Common Stock 21,546 $0.00 --
Tax Withholding Common Stock 7,380 $5.70 $42K
Holdings After Transaction: Restricted Stock Units — 321,368 shares (Direct); Common Stock — 202,707 shares (Direct)
Footnotes (1)
  1. The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Each RSU represents a contingent right to receive one share of Organon common stock. On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
New RSU grant 1 321,368 RSUs Granted March 31, 2026; vests 2027–2029 in three equal installments
New RSU grant 2 83,472 RSUs Granted March 31, 2026; vests 2027–2029 in three equal installments
2023 RSU grant size 36,139 RSUs Granted March 31, 2023; remaining one-third vested March 31, 2026
2025 RSU grant size 64,640 RSUs Granted March 31, 2025; one-third vested March 31, 2026
Tax-withheld shares 11,507 shares 4,127 and 7,380 common shares withheld at $5.70 for taxes
Common shares held 212,746 shares Direct Organon common stock holdings after March 31, 2026 transactions
Exercise shares 33,593 shares Common shares acquired via derivative exercises on March 31, 2026
Reference share price $5.70 per share Closing price used for tax-withholding dispositions on March 30, 2026
Restricted Stock Units financial
"The price is the closing market price of Organon & Co. common stock ... under which the Restricted Stock Units ("RSU") were awarded."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
contingent right financial
"Each RSU represents a contingent right to receive one share of Organon common stock."
derivative security financial
"transaction_type: "derivative" and transaction_action: "derivative exercise/conversion""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WALSH MATTHEW M

(Last)(First)(Middle)
C/O ORGANON & CO.
30 HUDSON STREET, FLOOR 33

(Street)
JERSEY CITY NEW JERSEY 07302

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/31/2026M12,047A$0202,707D
Common Stock03/31/2026F4,127D$5.7(1)198,580D
Common Stock03/31/2026M21,546A$0220,126D
Common Stock03/31/2026F7,380D$5.7(1)212,746D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(2)03/31/2026A321,368 (2) (2)Common Stock321,368$0321,368D
Restricted Stock Units(3)03/31/2026A83,472 (3) (3)Common Stock83,472$083,472D
Restricted Stock Units(4)03/31/2026M12,047 (5) (5)Common Stock12,047$00D
Restricted Stock Units(4)03/31/2026M21,546 (6) (6)Common Stock21,546$043,094D
Explanation of Responses:
1. The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
2. On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
3. On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
4. Each RSU represents a contingent right to receive one share of Organon common stock.
5. On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
6. On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Remarks:
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Matthew M. Walsh04/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Organon (OGN) CFO Matthew Walsh report in this Form 4?

Organon CFO Matthew Walsh reported new equity awards and related share movements. He received large RSU grants and saw earlier RSUs vest into common stock, with some shares withheld to cover tax obligations as part of standard equity compensation.

How many new restricted stock units did the Organon (OGN) CFO receive?

Walsh received two new RSU grants totaling 404,840 RSUs (321,368 and 83,472). Each RSU represents a contingent right to one share of Organon common stock, subject to future vesting over a defined three-year schedule beginning in 2027.

When will Matthew Walsh’s new Organon (OGN) RSU grants vest?

Both RSU grants vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Vesting means Walsh earns the right to receive common shares, subject to the plan’s service and other applicable conditions.

Were any Organon (OGN) shares sold by the CFO in this filing?

The filing shows tax-withholding dispositions, not open-market sales. A total of 4,127 and 7,380 shares of common stock were withheld at $5.70 per share to satisfy tax liabilities tied to vested RSUs, a common administrative mechanism.

How many Organon (OGN) shares does the CFO hold after these transactions?

After the reported transactions, Walsh directly holds 212,746 shares of Organon common stock. This figure reflects his position following RSU vesting, derivative exercises into common shares, and share withholding to cover associated tax obligations.

What prior Organon (OGN) RSU grants vested in this Form 4?

RSUs granted on March 31, 2023 and March 31, 2025 partially vested. One-third of a 36,139-unit 2023 grant vested on March 31, 2026, and one-third of a 64,640-unit 2025 grant vested the same day, converting into Organon common shares.